Metformin vs GLP-1s for PCOS: Which Goal Are You Treating?

Is metformin or a GLP-1 better for PCOS?

There is no single answer for every woman with PCOS. A treatment for metabolic risk, a treatment for obesity and a fertility plan are not interchangeable. The 2023 international PCOS guideline supports considering metformin for metabolic outcomes in appropriate adults; it also discusses GLP-1 medicines for higher weight using general population treatment guidance.¹ That is a framework for a conversation, not a ranking of prescriptions.

Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure here is cited inline to its primary source, the trial or the FDA label, so you can check it. This is background reading, not medical advice.

Before comparing prices or injections, name the result you want. Is your concern rising blood sugar, weight-related health problems, irregular cycles, preparing for pregnancy or several of these together? Ask the clinician to explain which goal a proposed medicine addresses and what will be measured to decide whether it is helping. A vague promise to “balance hormones” is much harder to evaluate.

Where does metformin fit?

The PCOS guideline specifically recommends considering metformin in adults with PCOS and a BMI of at least 25 for anthropometric and metabolic outcomes, including insulin resistance, glucose and lipids. It also allows consideration below that BMI while noting the more limited evidence.¹ A clinician should interpret that alongside your own history rather than deciding from BMI alone.

Metformin's US prescribing information is for type 2 diabetes, so a PCOS prescription involves off-label use.² Off-label does not mean unsupported; it means the reason for prescribing and the evidence behind it deserve an explicit explanation. Ask what the clinician expects to improve, what side effects to report and which follow-up tests are relevant to you.

Do not mistake metformin for a guarantee that PCOS will disappear. Nor should a modest change on the scale automatically count as failure if the treatment goal was metabolic health. Agree on the outcome before starting. Otherwise, you may judge a medication against a promise the evidence and the prescriber never made.

Where do GLP-1 medicines fit?

The international guideline discusses liraglutide and semaglutide as possible options for higher weight in adults with PCOS, alongside active lifestyle care and general population guidance.¹ The exact product still matters. A drug discussed in PCOS research is not automatically approved specifically for PCOS, and an obesity indication does not establish that it treats every symptom of the syndrome.

Our Ozempic and PCOS guide examines that distinction. If someone offers a GLP-1 as a complete PCOS solution, ask how it addresses your individual concern rather than accepting weight loss as a stand-in for every outcome. You can also use the PCOS weight-treatment guide to separate general obesity evidence from studies in people selected for PCOS.

Practical access is part of the decision. Ask whether the quoted amount includes the prescription, medication, consultations and follow-up. Ask what happens at a different dose and whether the price requires advance payment. Those questions do not decide which medicine is clinically appropriate, but they make a proposed long-term plan more realistic.

Does evidence after gestational diabetes answer the PCOS question?

Not by itself. The Diabetes Prevention Program studied people at high risk of developing type 2 diabetes. NIDDK reports that metformin reduced diabetes development relative to placebo and was particularly effective in women with a gestational-diabetes history.³ That finding concerns diabetes prevention in a defined population; it does not prove that metformin is superior to a GLP-1 for every woman with PCOS.

If both histories apply to you, bring both to the appointment. Ask whether the clinician is drawing on PCOS evidence, diabetes-prevention evidence or your current laboratory results. Our guide after gestational diabetes explains why these overlapping situations should not be collapsed into one generic “insulin resistance” claim.

Likewise, percentages from separate trials cannot create a head-to-head comparison. Different diagnoses, starting weights, medicines, follow-up periods and outcomes can make apparently simple comparisons misleading. A study that reports kilograms lost does not directly answer one that measures new diabetes cases.

What about pregnancy plans and tolerability?

Tell the prescriber whether pregnancy is possible and whether you hope to conceive. PCOS guidance calls for effective contraception when GLP-1 medicines are used and pregnancy is possible because pregnancy safety evidence is lacking.¹ This is not a fertility-treatment recommendation. Ask for a written plan for when treatment should stop and who will manage the transition.

Metformin has its own prescribing considerations, including kidney function and safety warnings in its label.² Its longer history of use does not make it a medication to borrow or restart without advice. A prior prescription is useful history; it is not proof that the same plan fits your current health or pregnancy situation.

For either approach, ask what to do if side effects interfere with meals, work or family life. Arrange a clear contact route before you need it. You should not have to choose between following an unclear schedule and waiting for a routine appointment with a problem that needs attention sooner.

What can the evidence tell you now?

The strongest useful conclusion is goal-specific. PCOS guidance supports several treatment paths, metformin has established metabolic and diabetes-prevention roles in appropriate populations, and branded GLP-1 eligibility must be assessed for the exact prescription.^1,2,3 This article does not establish a universal winner or a combination regimen. A credible plan connects your diagnosis, priorities, reproductive plans, affordable follow-up and a measurable definition of benefit.